CMS said that the proposed policies are projected to result in a net average year-over-year payment increase of 0.09% for Medicare Advantage plans in CY 2027.
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026, soundly beating Wall Street’s expectations. The healthcare giant accompanied its earnings beat with a bold 2026 financial forecast, projecting
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
As of January 16, 2026, the financial markets are navigating a complex "policy-driven tug-of-war" that has set the stage for a volatile yet potentially lucrative year. Investors are balancing the tailwinds of a Federal Reserve that is nearing the end of its easing cycle against the headwinds of an administration
As of mid-January 2026, the global financial markets are caught in a tense "wait-and-see" pattern. Investors are increasingly jittery as the delayed inflationary effects of aggressive 2025 trade policies begin to manifest in consumer prices. While many corporations spent the latter half of last year absorbing tariff costs through existing
As the 44th Annual J.P. Morgan Healthcare Conference kicked off this week in San Francisco, all eyes turned to UnitedHealth Group (NYSE:UNH), the diversified healthcare giant that serves as the primary barometer for the multi-trillion-dollar U.S. medical sector. On January 12, 2026, the company issued a critical
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and chronic shortages has evolved into a highly competitive, government-influenced market where affordability and accessibility have finally taken center
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
The long-standing dominance of Pharmacy Benefit Managers (PBMs) in the American healthcare system has reached a critical inflection point as 2025 draws to a close. For decades, these "middlemen" operated in the shadows, negotiating drug prices and rebates with manufacturers while managing prescription benefits for millions. However, a relentless wave
As the curtain closes on 2025, the investment community is witnessing a significant shift in sentiment regarding the managed care sector. Cigna Group (NYSE: CI) has become the centerpiece of this narrative, receiving a wave of analyst upgrades to ‘Buy’ in the final weeks of December. Market experts are increasingly
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
